CA
NZ
UK
AU
IND
US
No company announcement dated October 14, 2026 was found, so the 3.78% rise appears to follow the August 11 second-quarter report. Zura is developing tibulizumab, an antibody designed to act on the BAFF and IL-17 pathways, in two Phase 2 programmes. General and administrative …
No company release dated October 14, 2026 was identified, and an analyst action mentioned in the market feed could not be confirmed. The 3.59% gain therefore has no verified single trigger. In the August 18 report, Immatics said its anzu-cel cell therapy, which targets …
UnitedHealth Group published third-quarter results on October 13, 2026. Adjusted EPS of USD 4.69 compared with expectations of roughly USD 4.15, while revenue of USD 112.7 billion was 0.4% lower year over year but still above estimates. Management raised its 2026 adjusted EPS outlook …
No company statement dated October 14, 2026 was located to explain the 3.51% gain, which occurred on light trading. The latest company development was the September 28 announcement that IMPAVIDO was available in the United States. Eton said the drug treats visceral, cutaneous and …
No company announcement dated October 14, 2026 was found, making the 3.45% rise more consistent with continued reaction to the August 5 results than with fresh news. The incretin franchise led revenue growth of 48% to USD 22.97 billion. Mounjaro, Lilly’s tirzepatide product for …
With no company release dated October 14 identified, the 3.35% advance followed the October 8 quarterly update rather than a newly announced development. Product trends were mixed but generally stronger: Auryon atherectomy revenue climbed 14.7% to USD 18.9 million, NanoKnife irreversible electroporation revenue gained …
No October 14 corporate announcement was identified, so the share gain appears to have occurred against a backdrop of recent clinical and launch progress. Arrowhead said quarterly U.S. REDEMPLO (plozasiran) prescriptions approximately doubled, more than 400 individual prescribers had written for the medicine, and …
No corporate announcement dated October 14 was located, so the 3.1% increase appears to reflect the earlier settlement and anticipation of an important oncology meeting rather than a new disclosure. Xencor said Phase 1 results for XmAb819 in clear cell renal cell carcinoma had …
There was no company release dated October 14, 2026, and a relative-strength reading near 15 suggests the 3.1% rise may be an oversold bounce rather than a reaction to fresh news. Tonix sells TONMYA, a sublingual cyclobenzaprine product for fibromyalgia, as well as the …
No Corcept announcement dated October 14 was found; the 3.04% advance on thin trading appears to sit against its July results and upcoming regulatory dates. The FDA approved Lifyorli (relacorilant) with nab-paclitaxel for platinum-resistant ovarian cancer in March 2026, while a European decision was …
Please wait processing your request...